The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Linezolid in vitro: mechanism and antibacterial spectrum
Abstract
Oxazolidinones are prominent among the new Gram-positive antimicrobial agents now becoming available. They were discovered by DuPont Pharmaceuticals in the late 1980s but linezolid, the first analogue suitable for development, was found only when the family was re-examined by Pharmacia in the 1990s. Oxazolidinones bind to the 50S subunit of the prokaryotic ribosome, preventing formation of the initiation complex for protein synthesis. This is a novel mode of action; other protein synthesis inhibitors either block polypeptide extension or cause misreading of mRNA. Linezolid MICs vary slightly with the test method, laboratory, and significance attributed to thin hazes of bacterial survival, but all workers find that the susceptibility distributions are narrow and unimodal, with MIC values between 0.5 and 4 mg/L for streptococci, enterococci and staphylococci. Full activity is retained against Gram-positive cocci resistant to other antibiotics, including methicillin-resistant staphylococci and vancomycin-resistant enterococci. MICs are 4-8 mg/L for Moraxella, Pasteurella and Bacteroides spp. but other Gram-negative bacteria are resistant as a result of endogenous efflux activity. Resistance is difficult to select in vitro but has been reported during therapy in a few enterococcal infections and in two MRSA cases to date; the mechanism entails mutation of the 23S rRNA that forms the binding site for linezolid. Risk factors for selection of resistance include indwelling devices, undrained foci, protracted therapy and underdosage.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hiramatsu, K., Aritaka, N., Hanaki, H., Kawasaki, S., Hosoda, Y., Hori, S., Fukuchi, Y., & Kobayashi, I. (1997) · The Lancet · doi:10.1016/s0140-6736(97)07324-8 · Cited by 1,333
Linezolid resistance in a clinical isolate of Staphylococcus aureus
Tsiodras, S., Gold, H. S., Sakoulas, G., Eliopoulos, G. M., Wennersten, C., Venkataraman, L., Moellering, R. C., & Ferraro, M. J. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05410-1 · Cited by 1,033
Decreased Susceptibility of Streptococcus pneumoniae to Fluoroquinolones in Canada
Chen, D. K., McGeer, A., de Azavedo, J. C., & Low, D. E. (1999) · New England Journal of Medicine · doi:10.1056/nejm199907223410403 · Cited by 987
The Oxazolidinone Linezolid Inhibits Initiation of Protein Synthesis in Bacteria
Swaney, S. M., Aoki, H., Ganoza, M. C., & Shinabarger, D. L. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.12.3251 · Cited by 555
Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid
Gonzales, R. D., Schreckenberger, P. C., Graham, M. B., Kelkar, S., DenBesten, K., & Quinn, J. P. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04376-2 · Cited by 542
In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents
Zurenko, G. E., Yagi, B. H., Schaadt, R. D., Allison, J. W., Kilburn, J. O., Glickman, S. E., Hutchinson, D. K., Barbachyn, M. R., & Brickner, S. J. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.4.839 · Cited by 461
BSAC standardized disc susceptibility testing method
Testing, F. T. B. W. P. O. S., & Andrews, J. M. (2001) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/48.suppl_1.43 · Cited by 335
Reacher, M. H. (2000) · BMJ · doi:10.1136/bmj.320.7229.213 · Cited by 305
Prystowsky, J., Siddiqui, F., Chosay, J., Shinabarger, D. L., Millichap, J., Peterson, L. R., & Noskin, G. A. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.7.2154-2156.2001 · Cited by 302
Doern, G. V., Ferraro, M. J., Brueggemann, A. B., & Ruoff, K. L. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.4.891 · Cited by 297
Linezolid resistance in clinical isolates of Staphylococcus aureus
Wilson, P. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg104 · Cited by 289
Song, J., Lee, N. Y., Ichiyama, S., Yoshida, R., Hirakata, Y., Fu, W., Chongthaleong, A., Aswapokee, N., Chiu, C., Lalitha, M. K., et al. (1999) · Clinical Infectious Diseases · doi:10.1086/514783 · Cited by 258
Nosocomial Spread of Linezolid-Resistant, Vancomycin-Resistant Enterococcus faecium
Herrero, I. A., Issa, N. C., & Patel, R. (2002) · New England Journal of Medicine · doi:10.1056/nejm200203143461121 · Cited by 241
Kloss, P., Xiong, L., Shinabarger, D. L., & Mankin, A. S. (1999) · Journal of Molecular Biology · doi:10.1006/jmbi.1999.3247 · Cited by 213
Sahm, D. F., Marsilio, M. K., & Piazza, G. (1999) · Clinical Infectious Diseases · doi:10.1086/520195 · Cited by 213
Kalin, M., Örtqvist, Å., Almela, M., Aufwerber, E., Dwyer, R., Henriques, B., Jorup, C., Julander, I., Marrie, T. J., Mufson, M. A., et al. (2000) · The Journal of Infectious Diseases · doi:10.1086/315760 · Cited by 181
Linezolid-resistant enterococci: report of the first isolates in the United Kingdom
Auckland, C., Teare, L., Cooke, F., Kaufmann, M. E., Warner, M., Jones, G., Bamford, K., Ayles, H., & Johnson, A. P. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkf246 · Cited by 151
The in-vitro activity of linezolid (U-100766) and tentative breakpoints
Wise, R. A., Andrews, J. M., Boswell, F. J., & Ashby, J. P. (1998) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/42.6.721 · Cited by 149
Dresser, L., & Rybak, M. J. (1998) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1998.tb03109.x · Cited by 143
Henwood, C. J., Livermore, D. M., Johnson, A. P., James, D., Warner, M., & Gardiner, A. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/46.6.931 · Cited by 131
Self-citationGemmell, C. G. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkf192 · Cited by 120
Johnson, A. P., Tysall, L., Stockdale, M., Woodford, N., Kaufmann, M. E., Warner, M., Livermore, D. M., Asboth, F., & Allerberger, F. J. (2002) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-002-0807-0 · Cited by 118
Self-citationJones, R. N., Ballow, C. H., & Biedenbach, D. J. (2001) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(01)00235-8 · Cited by 92
Quinupristin/dalfopristin and linezolid: where, when, which and whether to use?
Livermore, D. M. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/46.3.347 · Cited by 89
Self-citationOxazolidinones: New antibacterial agents
Ford, C. W., Hamel, J. C., Stapert, D., Moerman, J. K., Hutchinson, D. K., Barbachyn, M. R., & Zurenko, G. E. (1997) · Trends in Microbiology · doi:10.1016/s0966-842x(97)01032-9 · Cited by 75
Johnson, A. P., Warner, M., & Livermore, D. M. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/45.2.225 · Cited by 67
Self-citationLivermore, D. M., Mushtaq, S., & Warner, M. (2001) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/48.3.452 · Cited by 35
Self-citationJohnson, A. P., Warner, M., Broughton, K., James, D., Efsratiou, A., George, R. C., & Livermore, D. M. (2001) · BMJ · doi:10.1136/bmj.322.7283.395 · Cited by 22
Self-citation
Cited by
Multidrug-resistance efflux pumps ? not just for resistance
Piddock, L. J. V. (2006) · Nature Reviews Microbiology · doi:10.1038/nrmicro1464 · Cited by 1,522
Clinically Relevant Chromosomally Encoded Multidrug Resistance Efflux Pumps in Bacteria
Piddock, L. J. V. (2006) · Clinical Microbiology Reviews · doi:10.1128/cmr.19.2.382-402.2006 · Cited by 1,231
Prevalence and Therapies of Antibiotic-Resistance in Staphylococcus aureus
Guo, Y., Song, G., Sun, M., Wang, J., & Wang, Y. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00107 · Cited by 870
Intrinsic antibiotic resistance: Mechanisms, origins, challenges and solutions
Cox, G., & Wright, G. D. (2013) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2013.02.009 · Cited by 697
Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline
Nahid, P., Mase, S. R., Migliori, G. B., Sotgiu, G., Bothamley, G. H., Brozek, J. L., Cattamanchi, A., Cegielski, J. P., Chen, L., Daley, C. L., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201909-1874st · Cited by 462
Metadata
- Authors
- Livermore, D. M.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-05-01
- Volume
- 51
- Issue
- 90002
- Pages
- 9ii-16
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2165999542
- Cited by
- 269
- References
- 28
- FWCI
- 7.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.